Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Optimización de la eficacia terapéutica de oligonucleótidos para el tratamiento de tumores sólidos mediante nanopartículas innovadoras

Resumen

Tipo:
Demanda Tecnológica
Referencia:
TRNL20180531001
Publicado:
11/06/2018
Caducidad:
12/06/2019
Resumen:
Una empresa holandesa de estadio clínico está desarrollando una nueva generación de nanomedicamentos. Su objetivo es utilizar su tecnología de nanopartículas para mejorar la eficacia y perfiles de seguridad de medicamentos actuales y nuevos para el tratamiento de tumores sólidos. La plataforma permite inducir moléculas terapéuticas, mejorar su farmacocinética en la administración intravenosa (IV) o subcutánea (SC) y dirigir las moléculas al tejido canceroso, donde estas moléculas se liberan de forma extracelular e intracelular. Como parte de su estrategia de desarrollo, la empresa busca laboratorios de investigación académicos para explotar sus nanopartículas mediante acuerdos de licencia y cooperación técnica.

Details

Tittle:
Optimization of therapeutic oligonucleotide efficacy for the treatment of solid tumours by innovative nanoparticles
Summary:
A Dutch clinical stage company is developing a new generation of nanomedicines. Their aim is to use their nanoparticle technology to improve the efficacy and safety profiles of current and novel drugs for the treatment of solid tumours.
As part of their development strategy, they are looking for a license and/or technical cooperation agreement with academic research labs to exploit their nanoparticles for enhanced tumour targeting of new oligonucleotides with therapeutic potential.
Description:
A Dutch clinical stage company developing a new generation of nanomedicines, aims to use their proprietary nanoparticle technology to improve the efficacy and safety profiles of current and novel drugs for the treatment of solid tumours.
In humans, their platform improves the pharmacokinetics and reduces life-threatening toxicities for drugs already used in the clinic. Moreover early signs of efficacy in humans have also been observed.
As part of the company´s development plan, they are looking for collaborative opportunities to exploit their nanoparticles for enhanced tumour targeting of new oligonucleotides with therapeutic potential.
Oligonucleotides, RNA (ribonucleic acid) or DNA (deoxyribonucleic acid), are of great therapeutic potential, as they may allow to act on to date undruggable targets, as well as utilising novel and unexplored mechanisms of action.
Despite this, selective tissue targeting of oligonucleotides has been a main challenge, as when administered naked they are unstable and may trigger undesired immunogenic responses. Effective targeting towards the appropriate intracellular compartment has also been a major hurdle thus far. These constraints have hampered the development of oligonucleotides in the clinic.
The company´s proprietary nanoparticle platform allows the entrapment of therapeutic molecules, to improve their pharmacokinetics upon intravenous (IV) or subcutaneous (SC) administration and to target them to cancer tissue where these molecules can be released extracellularly or intracellularly. The platform also offers the promise to target oligonucleotides to the applicable intracellular compartment. The client have generated initial in vivo proof of concept of enhanced oligonucleotide tumour targeting, cellular uptake, and knockdown of the target gene of interest.
To move forward the Dutch SME is looking for proprietary oligonucleotides having therapeutic potential that they can in-license and develop to the market in combination with their platform. The therapeutic candidate needs to fit the following criteria:
· Oligonucleotides having therapeutic potential for the treatment of solid tumours, e.g.:
¿ Gene expression modulating properties: siRNA (small interfering RNA), Antisense, shRNA (short hairpin RNA), miRNA (micro RNA), TFO (triplex forming oligonucleotides), or
¿ Immune stimulatory properties: CpG (C = cytosine triphosphate deoxynucleotide, p = phosphodiester link, G = guanine triphosphate deoxynucleotide), poly I:C (polyinosinic:polycytidylic acid) like oligonucleotides
¿ Other applicable mechanisms

The company is looking for a license and/or technical cooperation agreement with academic research labs to exploit their nanoparticles.

Technical Specification or Expertise Sought:
Biomedicine/biotechnology academic research labs with proprietary oligonucleotides with therapeutic potential for the treatment of solid tumours. Potential collaborators and their oligonucleotide should fit the following criteria:
· Proof of concept at least in vitro but preferably in vivo in a cancer model
· Patent protected (filed after 2013), or be patentable
· Oligonucleotide project must be active
The Dutch company envisions a partnership in which the academic partner performs the in vitro and in vivo evaluations of the applicable oligonucleotides upon entrapment in optimized nanoparticles with the company´s input.

Partner sought

Type and Role of Partner Sought:
The Dutch company is looking for a license agreement and/or a technical cooperation agreement with preferably an academic research lab that is open to licensing or partnering.
The SME envisions a partnership in which the academic partner performs the in vitro and in vivo evaluations of the applicable oligonucleotides upon entrapment in optimized nanoparticles with the company´s input.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Dutch
English
French